iShares MSCI World ETF Hits Record High Amid Index Reshuffle and Pharma Tariff Headwinds

iShares MSCI World ETF (URTH) reaches new peak at $205.72 despite index rebalance, overbought RSI of 94.6, US tariff risks, and Fed rate hold expectations.

The iShares MSCI World ETF (URTH) has scaled fresh highs even as it navigates a structural index overhaul, overheated technical signals, and a slate of sector-specific headwinds. After closing at a 52-week peak of $205.36 earlier this week, the fund pushed further to settle at $205.72 yesterday — a new all-time high. The rally has been impressive, with a 5.01% gain over the past 30 days, but the relative strength index now sits at 94.6, flagging severely overbought conditions.

Under the hood, the fund’s reference index underwent a significant technical reset. MSCI completed its May 2026 review on May 29, implementing changes to the MSCI World and broader ACWI indices. The free-float methodology — which determines what proportion of a company’s outstanding shares are considered available to foreign investors — was adjusted in a single step on June 1. This ripples directly into the weighting of individual securities, shifting the ETF’s composition without any market-driven price changes. Three new names entered the MSCI World as the largest additions by market cap: Medline A, MasTec, and TechnipFMC. Across the wider ACWI, 49 stocks were added and 101 removed.

The portfolio allocation has also shifted slightly in the process. BlackRock data from May 22 showed information technology commanding 29.62% of the fund, with financials at 15.52% and industrials at 11.23%. More recent readings put the tech weighting at 27.61%, reflecting the free-float adjustments and the index rebalance. Geographically, the US remains dominant at 72.08% of market value, followed by Japan (5.66%), the UK (3.55%), Canada (3.37%), and France (2.37%).

That heavy US tilt means URTH is particularly exposed to domestic macro risk. A fresh set of pharmaceutical tariffs is weighing on the healthcare segment, which accounts for roughly 10% of the portfolio. The US is now levying 15% on patented drugs from the EU, Japan, South Korea, and Switzerland, with a 10% rate for British products. Companies without pre-existing pricing agreements face potential 100% duties, and FactSet has already cut earnings expectations for the sector. Meanwhile, the Federal Reserve’s new chair, Kevin Warsh, who took over on May 15, faces his first policy meeting on June 17. Markets assign a 97% probability that the Fed will hold rates steady, as US inflation sits at a three-year high of 3.8% and wage growth stagnates at 3.6%. Goldman Sachs and Bank of America have both scrapped their rate-cut forecasts for 2026. For a fund where tech is the largest sector weighting, elevated rates continue to pressure valuations.

Concentration risk remains a defining feature. Nvidia is the top single holding at 6.36%, followed by Apple at 4.86% and Microsoft at 3.21%. These three names alone drive a double-digit share of total performance. Yet diversification cuts both ways: when Nvidia reported May-quarter revenue of $81.6 billion (up 85% year-on-year), URTH edged up just 0.29%, while Nvidia itself fell 1.78%.

On the dividend front, URTH goes ex-dividend on June 15 with a payout of $1.26 per share — 16% less than the $1.50 distributed in December 2025. The trailing three-year dividend growth rate stands at 8.52% annually, with a one-year increase of 18.5%. The fund’s expense ratio is 0.24%, which Morningstar still considers a Gold-rated offering thanks to a tracking difference of just 0.02%. BlackRock’s fee has come under pressure as competitors slash pricing: Invesco cut a comparable product to 0.05%, and UBS and BNP Paribas have followed. Nevertheless, investors keep piling in — net inflows over the past twelve months reached $1.86 billion.

A wildcard on the horizon is SpaceX. The company confidentially filed for an IPO in April, and a Nasdaq listing is expected this summer at a potential valuation of $1.75 trillion. Under MSCI’s fast-entry rules, SpaceX could be added to the MSCI World within 15 trading days, triggering an estimated $12 billion in index-driven buying. For a passive fund that already holds 72% in US equities, absorbing a newly listed mega-cap would be an automatic, non-discretionary process.

The next key test comes June 5 with the US jobs report. Strong payroll numbers would further dim rate-cut hopes, while weak data could fuel the tech rally and keep URTH at its record levels. For now, the fund sits at the intersection of a completed index rebuild, stretched technicals, and an unusually dense slate of macro and event risk.